Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-22 for chronic sialorrhea (phase II/III)
jRCT2031240163Phase 3Active, not recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of scopolamine in hypersalivation (3 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Change in salivary flow rate at 4 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
scopolamine
03
Conditions
hypersalivation
Beyond the preview
Go deeper on jRCT2031240163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240163.